BR112012000953A2 - compostos de ligação específica a bactérias gram-positivas - Google Patents

compostos de ligação específica a bactérias gram-positivas

Info

Publication number
BR112012000953A2
BR112012000953A2 BR112012000953A BR112012000953A BR112012000953A2 BR 112012000953 A2 BR112012000953 A2 BR 112012000953A2 BR 112012000953 A BR112012000953 A BR 112012000953A BR 112012000953 A BR112012000953 A BR 112012000953A BR 112012000953 A2 BR112012000953 A2 BR 112012000953A2
Authority
BR
Brazil
Prior art keywords
gram
specific binding
positive bacteria
binding compounds
compounds
Prior art date
Application number
BR112012000953A
Other languages
English (en)
Other versions
BR112012000953A8 (pt
Inventor
Eric J Brown
John Hiroshi Morisaki
Kimberly Kajihara
Mark Jeroen Kwakkenbos
Sanjeev Mariathasan
Tim Beaumont
Wouter L W Hazenbros
Yi Xia
Original Assignee
Aimmtherapeutics B V
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aimmtherapeutics B V, Genentech Inc filed Critical Aimmtherapeutics B V
Publication of BR112012000953A2 publication Critical patent/BR112012000953A2/pt
Publication of BR112012000953A8 publication Critical patent/BR112012000953A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physiology (AREA)
BR112012000953A 2009-07-15 2010-07-15 anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias BR112012000953A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22587809P 2009-07-15 2009-07-15
EP09165558 2009-07-15
PCT/NL2010/050456 WO2011008092A2 (en) 2009-07-15 2010-07-15 Gram-positive bacteria specific binding compounds

Publications (2)

Publication Number Publication Date
BR112012000953A2 true BR112012000953A2 (pt) 2016-11-22
BR112012000953A8 BR112012000953A8 (pt) 2017-12-26

Family

ID=41467048

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000953A BR112012000953A8 (pt) 2009-07-15 2010-07-15 anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias

Country Status (24)

Country Link
US (9) US20110020323A1 (pt)
EP (1) EP2454284B1 (pt)
JP (3) JP6192294B2 (pt)
KR (1) KR101832201B1 (pt)
CN (2) CN102666583B (pt)
AR (1) AR077756A1 (pt)
AU (2) AU2010271582B2 (pt)
BR (1) BR112012000953A8 (pt)
CA (1) CA2768204A1 (pt)
DK (1) DK2454284T3 (pt)
EA (1) EA031447B1 (pt)
ES (1) ES2673323T3 (pt)
HK (1) HK1222418A1 (pt)
HU (1) HUE038277T2 (pt)
IL (3) IL217497A (pt)
MX (1) MX350234B (pt)
NZ (2) NZ598063A (pt)
PL (1) PL2454284T3 (pt)
SG (2) SG10201704269RA (pt)
SI (1) SI2454284T1 (pt)
TR (1) TR201809128T4 (pt)
TW (2) TWI502068B (pt)
WO (1) WO2011008092A2 (pt)
ZA (2) ZA201200363B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974017B2 (en) 2005-12-09 2023-06-21 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for influencing the stability of antibody producing cells
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
JP5781508B2 (ja) 2009-07-15 2015-09-24 アイム・セラピューティクス・べー・フェー 高親和性抗体を産生させるための手段および方法
SI2454284T1 (en) 2009-07-15 2018-07-31 Aimm Therapeutics B.V. Compounds that specifically bind to Gram-positive bacteria
EP2646466B1 (en) * 2010-12-02 2017-03-29 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
CN102559733A (zh) * 2012-03-13 2012-07-11 黑龙江省科学院微生物研究所 导入clfA基因的乳酸乳球菌基因工程菌株的构建方法
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
MX375324B (es) 2012-11-06 2025-03-06 Medimmune Llc Anticuerpos contra determinantes de la superficie de s. aureus.
WO2014142117A1 (ja) 2013-03-12 2014-09-18 全薬工業株式会社 抗ブドウ球菌抗体、その製造方法並びにその使用
AR095199A1 (es) * 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
US9803002B2 (en) 2013-05-31 2017-10-31 Genentench, Inc. Anti-wall teichoic antibodies and conjugates
LT3004162T (lt) * 2013-05-31 2020-06-10 Genentech, Inc. Antikūnai prieš ląstelės sienelės teicho rūgštį ir konjugatai
JP6506262B2 (ja) 2013-05-31 2019-04-24 ジェネンテック， インコーポレイテッド 抗細胞壁タイコ酸抗体及びコンジュゲート
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
US10556963B2 (en) 2013-12-17 2020-02-11 Aimm Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
AU2015211480B2 (en) 2014-01-31 2020-05-14 Kling Biotherapeutics B.V. Means and methods for producing stable antibodies
BR112017011478A2 (pt) * 2014-12-03 2018-02-27 Genentech, Inc. composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
HK1243931A1 (zh) * 2014-12-03 2018-07-27 F. Hoffmann-La Roche Ag 抗金黄色葡萄球菌抗体利福霉素缀合物及其用途
WO2016200926A1 (en) * 2015-06-09 2016-12-15 Techulon Inc. Peptide nucleic acid molecules for treatment of gram positive bacterial infection
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
SMT202300418T1 (it) 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
EP3630179A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
US11280788B2 (en) 2019-01-31 2022-03-22 Fresenius Medical Care Holdings, Inc. Rapid diagnosis of peritonitis in peritoneal dialysis patients
KR102301987B1 (ko) * 2019-11-14 2021-09-13 연세대학교 산학협력단 항체 선별 방법, 박테리아 오염 진단 방법 및 박테리아 오염 진단 키트
WO2022087402A1 (en) 2020-10-23 2022-04-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
US20250064921A1 (en) * 2021-12-28 2025-02-27 Cz Biohub Sf, Llc Chemically modified bacterial peptidoglycan compositions and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501418A (ja) 1994-06-07 1998-02-10 ザ・ロックフェラー・ユニバーシティ 黄色ぶどう球菌の表面蛋白
US6994855B1 (en) 1994-08-22 2006-02-07 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
CN1113102C (zh) 1995-01-30 2003-07-02 彼得·特鲁格 抗肿瘤制剂
SE9602496D0 (sv) 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6680195B1 (en) 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US6692739B1 (en) * 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6703025B1 (en) * 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
EP1121149A4 (en) 1998-08-31 2002-03-20 Inhibitex Inc IMMUNOTHERAPEUTICS AGAINST STAPHYLOCOCCUS USING DONOR SELECTION AND DONOR STIMULATION
KR100644953B1 (ko) 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
EP1117772B1 (en) 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US20030165527A1 (en) 1998-12-22 2003-09-04 Bengt Guss Novel fibronectin-binding protein
US20040038327A1 (en) 1999-08-31 2004-02-26 Foster Timothy J. Antibodies to polypeptides from coagulase-negative staphylococci
PT1377314E (pt) 2001-01-26 2012-01-02 Inhibitex Inc Anticorpos monoclonais para a proteína clfa e método de utilização no tratamento ou prevenção de infecções
GB0127983D0 (en) * 2001-11-22 2002-01-16 Neutec Pharma Plc Treatment of micro-organism infection
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
AU2003274972A1 (en) 2002-09-13 2004-04-30 Inhibitex, Inc. Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
US20040151737A1 (en) 2003-02-05 2004-08-05 University Of Tennessee Streptococcal serum opacity factors and fibronectin-binding proteins and peptides thereof for the treatment and detection of streptococcal infection
BRPI0408167B1 (pt) 2003-03-07 2014-10-21 Wyeth Corp Conjugados de polissacarídeo-proteína veículo adesina da superfície estafilocócica para imunização contra infecções nosocomiais
US20070026011A1 (en) 2003-05-29 2007-02-01 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
KR101270829B1 (ko) * 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1850867A1 (en) * 2005-01-10 2007-11-07 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
WO2006138627A2 (en) 2005-06-16 2006-12-28 Inhibitex, Inc. Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein
WO2007100580A2 (en) 2006-02-22 2007-09-07 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
CA2682292A1 (en) * 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
CN101302504B (zh) * 2007-05-11 2011-12-21 上海高科联合生物技术研发有限公司 一种抗体亲和层析纯化溶葡萄球菌酶的方法
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
US20090162379A1 (en) 2007-10-01 2009-06-25 Magnus Hook Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
PL2244722T3 (pl) 2008-01-31 2017-04-28 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Leczenie zakażeń drobnoustrojami
SG187517A1 (en) 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
WO2010005513A2 (en) 2008-06-30 2010-01-14 The Texas A&M University System Crystal structure of staphylococcus aureus clumping factor a in complex with fibrinogen derived peptide and uses thereof
HUE036372T2 (hu) 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
SI2454284T1 (en) 2009-07-15 2018-07-31 Aimm Therapeutics B.V. Compounds that specifically bind to Gram-positive bacteria
ES2625979T3 (es) 2009-07-16 2017-07-21 Glaxosmithkline Biologicals S.A. Tratamiento de infecciones

Also Published As

Publication number Publication date
ES2673323T3 (es) 2018-06-21
AU2010271582B2 (en) 2016-07-28
CN102666583B (zh) 2015-11-25
SG10201704269RA (en) 2017-06-29
CN102666583A (zh) 2012-09-12
AU2016250398B2 (en) 2018-09-27
EA031447B1 (ru) 2019-01-31
TW201107470A (en) 2011-03-01
US9266943B2 (en) 2016-02-23
US20140235828A1 (en) 2014-08-21
WO2011008092A4 (en) 2011-07-07
DK2454284T3 (en) 2018-07-02
JP6192294B2 (ja) 2017-09-06
TWI502068B (zh) 2015-10-01
SG177653A1 (en) 2012-02-28
US20170067880A1 (en) 2017-03-09
AU2010271582A2 (en) 2013-05-16
HK1222418A1 (zh) 2017-06-30
HUE038277T2 (hu) 2018-10-29
WO2011008092A2 (en) 2011-01-20
US20180292391A1 (en) 2018-10-11
IL217497A (en) 2015-11-30
US9927428B2 (en) 2018-03-27
JP2018134089A (ja) 2018-08-30
KR20120065326A (ko) 2012-06-20
AU2016250398A1 (en) 2016-11-17
TW201610153A (zh) 2016-03-16
US9688745B2 (en) 2017-06-27
US20160222096A1 (en) 2016-08-04
CN105440133A (zh) 2016-03-30
EP2454284B1 (en) 2018-04-11
US9399673B2 (en) 2016-07-26
EA201390967A1 (ru) 2014-01-30
KR101832201B1 (ko) 2018-02-28
EP2454284A2 (en) 2012-05-23
MX350234B (es) 2017-08-30
IL238074A (en) 2016-06-30
JP2016135771A (ja) 2016-07-28
TR201809128T4 (tr) 2018-07-23
US9090677B2 (en) 2015-07-28
IL242207A0 (en) 2015-11-30
SI2454284T1 (en) 2018-07-31
US20150376266A1 (en) 2015-12-31
US20130253175A1 (en) 2013-09-26
ZA201200363B (en) 2014-06-25
US20110020323A1 (en) 2011-01-27
CA2768204A1 (en) 2011-01-20
US20130261293A1 (en) 2013-10-03
WO2011008092A3 (en) 2011-05-26
AU2010271582A1 (en) 2012-03-01
US20160168232A9 (en) 2016-06-16
IL217497A0 (en) 2012-02-29
BR112012000953A8 (pt) 2017-12-26
NZ616921A (en) 2015-06-26
US8617556B2 (en) 2013-12-31
US20120157665A1 (en) 2012-06-21
PL2454284T3 (pl) 2018-09-28
NZ598063A (en) 2014-07-25
AR077756A1 (es) 2011-09-21
US9458228B2 (en) 2016-10-04
ZA201400644B (en) 2015-10-28
JP2012533293A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
BR112012000953A2 (pt) compostos de ligação específica a bactérias gram-positivas
BRPI0923155A2 (pt) scfcs de ligação a sparc
EP2483254A4 (en) NEW COMPOUNDS
IL213325A0 (en) Antibacterial compounds
GB0905955D0 (en) Novel compounds
DE112009003886A5 (de) Kupplungsaggregat
GB0903565D0 (en) A damper
GB2475221B (en) A book
DE112009003885A5 (de) Kupplungsaggregat
ZA201102554B (en) Intermediate moisture bar using a dairy-based binder
GB2481406B (en) A resolver
DE112010004333A5 (de) Kupplungsaggregat
ZA201202350B (en) Antibiotic compounds
IL214028A0 (en) A novel cyanopyrimidine derivative
GB2481085C (en) A convertible mat
BRPI1015928A2 (pt) tubo de distribuição controlável remotamente
DE112010004396A5 (de) Kupplungsaggregat
EP2413977A4 (en) DRYING DEVICE
GB2500516B (en) A book
IT1397375B1 (it) Cassero a disarmo rapido
IT1395048B1 (it) Un predellino per veicoli
PH32009000780S1 (en) A stapler
FI8370U1 (fi) Kuristin
FI20090295A0 (fi) Sideaine
GB0909776D0 (en) Ad jogger

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL